Measuring walking quality in people with Multiple Sclerosis using camera technology
Development of Camera Based Gait Deviation Index for Persons With Multiple Sclerosis
Shirley Ryan AbilityLab · NCT06516458
This study is testing a new tool that uses camera technology to measure how well people with Multiple Sclerosis walk, to help doctors improve their treatment plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Shirley Ryan AbilityLab (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06516458 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a new measurement tool called the Gait Deviation Index (GDI) specifically for individuals with Multiple Sclerosis (MS). By utilizing camera-based tracking to analyze body position during walking, the study seeks to create an objective and easily interpretable measure of gait quality. The GDI has previously been validated for spinal cord injury patients, but this research will adapt it for MS patients, enabling clinicians to better track progress and tailor rehabilitation strategies. Ultimately, the goal is to enhance the effectiveness of therapy for those living with MS.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 with a diagnosis of relapsing form of Multiple Sclerosis who can walk independently and have been relapse-free for at least one month.
Not a fit: Patients with orthopedic injuries or other conditions that affect their ability to walk will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide clinicians with a reliable tool to assess and improve walking quality in patients with Multiple Sclerosis.
How similar studies have performed: While the Gait Deviation Index has shown success in spinal cord injury populations, its application in Multiple Sclerosis is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS) * Able to ambulate overground * Relapse free for at least 1 month * Age ≥18 and ≤ 75 years * Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening Exclusion criteria: \- Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing
Where this trial is running
Chicago, Illinois
- Shirley Ryan AbilityLab — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Milap Sandhu, PhD — Shirley Ryan AbilityLab
- Study coordinator: Weena Dee
- Email: wdee@sralab.org
- Phone: 312-328-7503
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis, Relapsing-Remitting